Bio-Rad Laboratories Inc. (BIO)
Bio-Rad Laboratories Statistics
Share Statistics
Bio-Rad Laboratories has 27.98M shares outstanding. The number of shares has increased by -1.66% in one year.
Shares Outstanding | 27.98M |
Shares Change (YoY) | -1.66% |
Shares Change (QoQ) | 0.31% |
Owned by Institutions (%) | 71% |
Shares Floating | 23.46M |
Failed to Deliver (FTD) Shares | 18 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 662.32K, so 2.36% of the outstanding shares have been sold short.
Short Interest | 662.32K |
Short % of Shares Out | 2.36% |
Short % of Float | 2.83% |
Short Ratio (days to cover) | 3.94 |
Valuation Ratios
The PE ratio is -5.03 and the forward PE ratio is 32.38. Bio-Rad Laboratories's PEG ratio is -0.03.
PE Ratio | -5.03 |
Forward PE | 32.38 |
PS Ratio | 3.61 |
Forward PS | 2.3 |
PB Ratio | 1.41 |
P/FCF Ratio | 34.82 |
PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bio-Rad Laboratories.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
Current Ratio | 2.58 |
Quick Ratio | 2.58 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.08 |
Debt / FCF | 0.65 |
Interest Coverage | 5.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $333.31K |
Profits Per Employee | $-239.51K |
Employee Count | 7,700 |
Asset Turnover | 0.27 |
Inventory Turnover | n/a |
Taxes
Income Tax | -498.3M |
Effective Tax Rate | 21.27% |
Stock Price Statistics
The stock price has increased by -25.34% in the last 52 weeks. The beta is 0.98, so Bio-Rad Laboratories's price volatility has been higher than the market average.
Beta | 0.98 |
52-Week Price Change | -25.34% |
50-Day Moving Average | 288.57 |
200-Day Moving Average | 317.07 |
Relative Strength Index (RSI) | 36.92 |
Average Volume (20 Days) | 296.07K |
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B and earned -1.84B in profits. Earnings per share was -65.36.
Revenue | 2.57B |
Gross Profit | 1.38B |
Operating Income | 269M |
Net Income | -1.84B |
EBITDA | -2.14B |
EBIT | -2.29B |
Earnings Per Share (EPS) | -65.36 |
Balance Sheet
The company has 0 in cash and 174.3M in debt, giving a net cash position of -174.3M.
Cash & Cash Equivalents | 0 |
Total Debt | 174.3M |
Net Cash | -174.3M |
Retained Earnings | 7.42B |
Total Assets | 9.36B |
Working Capital | 2.56B |
Cash Flow
In the last 12 months, operating cash flow was 455.2M and capital expenditures -189M, giving a free cash flow of 266.2M.
Operating Cash Flow | 455.2M |
Capital Expenditures | -189M |
Free Cash Flow | 266.2M |
FCF Per Share | 9.44 |
Margins
Gross margin is 53.73%, with operating and profit margins of 10.48% and -71.86%.
Gross Margin | 53.73% |
Operating Margin | 10.48% |
Pretax Margin | -91.27% |
Profit Margin | -71.86% |
EBITDA Margin | -83.46% |
EBIT Margin | 10.48% |
FCF Margin | 10.37% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for BIO is $417.5, which is 70.4% higher than the current price. The consensus rating is "Buy".
Price Target | $417.5 |
Price Target Difference | 70.4% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Stock Splits
The last stock split was on Mar 8, 2002. It was a forward split with a ratio of 2:1.
Last Split Date | Mar 8, 2002 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 1.58 |
Piotroski F-Score | 6 |